The term “pothead” might take on a new connotation in the future. A recent study indicates that low doses of THC, the active component in cannabis, could potentially protect memory and decrease brain damage associated with Alzheimer’s when paired with an anti-inflammatory medication.
This research, primarily conducted on mice, brings some optimism as both drugs involved are already commonly used, possibly accelerating human trials.
Dr. Chu Chen from UT Health San Antonio pointed out that developing new medications often takes a decade or two, but since these drugs are already approved, it “[gives] us a real advantage.”
This advancement is particularly significant, given that over 7 million Americans have Alzheimer’s, a figure projected to nearly double by 2060 unless new preventive methods emerge.
Rising Expectations
In recent years, the benefits of THC have garnered attention, revealing properties that might alleviate inflammation and protect neurons. The FDA has already sanctioned synthetic forms of THC for treating nausea and appetite loss in cancer and HIV patients.
Nevertheless, THC isn’t without its drawbacks. Some studies suggest it can impair learning and memory, leaving researchers puzzled about the underlying causes. Thus, Chen commenced his investigation.
He discovered that an enzyme called COX-2, which is linked to inflammation, plays a critical role in cognitive function. Normally present at low levels in a healthy brain, COX-2 spikes during injury or disease, contributing to cognitive decline when overactive.
Chen’s work revealed an unexpected increase in COX-2 levels in the brain with THC administration, which aligned with learning and memory issues.
Prior attempts to provide COX-2 inhibitors to Alzheimer’s patients failed to show cognitive improvement and were associated with severe cardiovascular risks. Chen’s findings offer a fresh perspective.
Small Doses, Significant Impact
Endocannabinoids, naturally occurring in the brain, interact with the same receptors as THC but often yield opposite effects. One in particular, 2-AG, reduces COX-2 activity and lessens neuroinflammation.
Chen theorized if it’d be possible to mitigate THC’s inflammatory impact while retaining its positive effects. The preliminary results seem promising, particularly with celecoxib, a widely used anti-inflammatory drug.
In the conducted study, researchers administered very low doses of both THC and celecoxib to mice, avoiding levels previously linked to heart issues in Alzheimer’s trials. The dosage equated to approximately 18 mg of THC and 6 mg of celecoxib for a person weighing 165 pounds.
They assessed the combination using two Alzheimer’s mouse models, targeting key features of the disease such as beta-amyloid plaques and tau tangles. This treatment commenced before any memory issues were apparent in the mice, enabling researchers to explore potential preventative effects over a 30-day period.
The results showed that while low-dose THC provided some cognitive enhancement, it also increased inflammatory indicators. Conversely, the combination with celecoxib led to notably better outcomes, improving learning and memory, reducing both beta-amyloid plaques and tau tangles, alongside lowering inflammation markers. Additionally, gene expressions related to brain health shifted to more favorable levels post-treatment.
Ultimately, Chen emphasized the importance of behavioral outcomes, stating that effective cognition improvement was the ultimate goal, and the combination outperformed THC alone in this regard.
Looking Ahead
The research team is gearing up for additional studies aimed at investigating whether this drug combination might slow the progression of Alzheimer’s or even reverse some damage once symptoms emerge.
Chen remarked on the lengthy journey to this point, highlighting that foundational neuroscience discoveries could finally pave the way for clinical applications.
Experts believe that even a slight delay in Alzheimer’s onset could yield significant benefits for patients, families, and the overall healthcare system. Alzheimer’s affects far more than memory; it gradually erodes aspects like personality and reasoning—eventually hindering even simple daily tasks.
People typically have a lifespan of four to eight years following diagnosis, with Alzheimer’s ranked as the sixth leading cause of death among those aged 65 and older as of 2022.
The statistics are concerning: More than one in nine individuals aged 65 and up have Alzheimer’s. A recent study predicted that around 42% of Americans over 55 may face dementia in later years, with Alzheimer’s being the most frequent form.
Surveys reveal that an overwhelming 92% of Americans would consider taking a medication to slow down the disease, with nearly three in five willing to accept moderate to high risks for such treatment.
